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Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by homozygous expansion of a GAA⋅TTC
trinucleotide repeat within the first intron of the FXN gene, leading to reduced FXN transcription and decreased levels of frataxin
protein. Recent advances in FRDA research have revealed the presence of several epigenetic modifications that are either directly
or indirectly involved in this FXN gene silencing. Although epigenetic marks may be inherited from one generation to the next,
modifications of DNA and histones can be reversed, indicating that they are suitable targets for epigenetic-based therapy. Unlike
other trinucleotide repeat disorders, such asHuntington disease, the large expansions ofGAA⋅TTC repeats in FRDAdonot produce
a change in the frataxin amino acid sequence, but they produce reduced levels of normal frataxin.Therefore, transcriptional reacti-
vation of the FXN gene provides a good therapeutic option.The present paper will initially focus on the epigenetic changes seen in
FRDA patients and their role in the silencing of FXN gene and will be concluded by considering the potential epigenetic therapies.
1. Introduction
FRDA is a rare autosomal recessive neurodegenerative disor-
der that affects approximately 1-2 in 50,000 Caucasians [1]. In
96% of FRDA patients, the disease is caused by homozygous
expansion of GAA⋅TTC repeats in intron 1 of the FXN gene
[2]. Unaffected individuals have up to 40 GAA⋅TTC repeats,
with a premutation range from 41 to 65 GAA repeats. The
affected individuals contain 66 to 1700 GAA⋅TTC repeats [3],
most commonly between 600 and 900 GAA⋅TTC repeats.
In most cases, the GAA⋅TTC repeat number of the smaller
allele is directly related to the age of onset and the severity of
the disease. However, a small proportion of patients (approx-
imately 4%) are compound heterozygous, having one allele
with a GAA⋅TTC repeat expansion and the other allele with
an inactivating (or loss-of-function) intragenic mutation,
such as a point mutation [4, 5] or a deletion/duplication [6–
9]. To date, no confirmed FRDA patients have been identified
without at least one GAA⋅TTC repeat expansion.
The exact mechanism underlying the GAA⋅TTC repeat
expansion in FRDA is not fully understood, but evidence
has been put forward for the involvement of abnormal
DNA replication, transcription, or repair [10–12]. In FRDA
patients, the expanded GAA⋅TTC repeats produce a marked
reduction in the mitochondrial protein frataxin, ranging
from4% to 29%of normal levels [13].However, asymptomatic
carriers produce about 50% of frataxin protein compared
to the unaffected individuals [14]. Therefore, drugs that are
able to increase frataxin expression, at least to the levels
of the healthy carriers, would be beneficial. Reduced levels
of frataxin protein in FRDA patients are associated with
an imbalance of iron-sulfur (Fe-S) cluster biosynthesis [15],
mitochondrial iron accumulation in heart, spinal cord, and
dentate nucleus [16–18], and increased susceptibility to oxida-
tive stress [19]. The outcome is progressive spinocerebellar
neurodegeneration, causing symptoms of incoordination,
muscle weakness, and sensory loss. There is also a patho-
logical involvement of nonneuronal tissues with cardiomy-
opathy as a common secondary effect and diabetes found in
approximately 10% of FRDA patients [20]. At present, there
is no effective therapy for FRDA, and affected individuals
generally die in early adulthood from the associated heart
disease. Therefore, there is a high unmet clinical need to
develop a therapy for this devastating disorder.
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In view of the current knowledge regarding the FRDA
pathology, some effort has been put into investigating the
therapeutic interventions aimed at ameliorating secondary
disease effects, such as oxidative stress and mitochondrial
iron accumulation. Thus far, FRDA preclinical and clinical
trials using antioxidants and iron chelators have demon-
strated some limited success [20]. However, a more effective
therapymay be achieved by targeting the immediate effects of
the GAA⋅TTC repeat expansion mutation itself or the mech-
anisms by which the GAA⋅TTC repeat expansion induces the
impairment of frataxin expression. Although these mecha-
nisms are currently not known, two nonexclusive hypotheses
have been put forward. Firstly, it has been suggested that
the GAA⋅TTC repeat expansion may adopt abnormal non-
B DNA structures (triplexes or “sticky DNA”) or DNA⋅RNA
hybrid structures (R loops), which impede the process of
RNA polymerase and thus reduce FXN gene transcription
[21, 22]. Secondly, there is an evidence originally from posi-
tion effect variegation (PEV) studies in transgenic mice that
GAA⋅TTC repeat expansions can produce heterochromatin-
mediated gene silencing effects [23]. Consistent with the
latter hypothesis, several FRDA disease-related epigenetic
changes have been identified in the immediate vicinity of
the expanded GAA⋅TTC repeats of the FXN gene, and these
changes will be discussed further in this paper.
2. Epigenetic Changes in FRDA
Epigenetic mechanisms, which include DNA methylation,
histone modification, chromatin remodeling, and noncod-
ing RNAs, result in heritable changes in gene expression
that do not involve changes in DNA sequence. Epigenetic
mechanisms play a crucial role in silencing or activation of
many genes during development. Recognition of the role of
epigenetics in human disease started with oncology, but it
has now extended to other disciplines, such as neurodevelop-
ment and neurodegenerative disorders, including Alzheimer
disease (AD), Parkinson disease (PD), Huntington disease
(HD), fragile X syndrome (FRAXA), and FRDA. Although
epigenetic-based silencing of genes is a complicated pro-
cess, three main steps have been described [24]. Firstly,
the specific silencing complexes move towards the DNA
sequence that is to be inactivated. Secondly, the inhibition
of RNA polymerases or other nuclear enzymes takes place.
Thirdly, perhaps the most crucial step in epigenetic silencing
is the propagation of silent chromatin into the daughter cells
[24]. It is not certain how the chromatin modifications, or
“epigenetic marks,” that are established during transcription
can be inherited by daughter cells. Although most of the his-
tone modifications are reversible by epigenetic manipulation
(epigenetic therapy), an effective target-specific method of
reversing these modifications at a particular gene locus is yet
to be achieved. The potential role of epigenetic mechanisms
in FRDA was initially highlighted by the finding that long
GAA⋅TTC repeats were able to suppress the expression
of a nearby heterochromatin-sensitive cell surface reporter
gene (hCD2) in transgenic mice by a phenomenon called
position effect variegation (PEV) [23]. Further studies have
subsequently led to the identification of epigenetic changes,
including DNA methylation and histone deacetylation and
methylation modifications, which may be involved in FXN
gene silencing in FRDA.
2.1. DNAMethylation. DNAmethylation is a covalent modi-
fication ofDNAby the addition ofmethyl residues to cytosine
bases in DNA. It is the most widely studied epigenetic
mechanism in several diseases, especially cancer, providing a
stable gene silencingmechanism that plays an essential role in
regulating gene expression and chromatin architecture. The
process of DNA methylation is carried out by DNA methyl-
transferase (DNMT) enzymes, which catalyze the covalent
addition of a methyl group from S-adenosylmethionine
(SAM) to the 5󸀠 position of cytosine, predominantly within
CpG dinucleotides ([25], reviewed in [26]). In mammals, the
DNMT family includes three functional proteins: DNMT1,
DNMT3a, and DNMT3b [27], with the most abundant
being DNMT1 [25]. DNMT1 preferentially methylates hemi-
methylated DNA and is thus responsible for methylation
during DNA replication [28]. It plays a key role in imprint-
ing and X-chromosome inactivation during embryogenesis
[29]. DNMT3a and DNMT3b have an equal preference for
hemimethylated and nonmethylated DNA and so have been
classified as de novomethyltransferases [30].They are respon-
sible for de novo DNA methylation during embryogenesis
[30, 31].
Studies that have investigated the DNA methylation
profiles of transcriptionally silenced genes have revealed
a strong correlation between promoter DNA methylation
and transcriptional silencing. However, it has also been
reported that intragenic DNA methylation can contribute to
transcriptional gene silencing [32]. In addition, genome-wide
studies in cancer cells have highlighted the fact that the genes
that are already silenced by Polycomb complexes are more
susceptible to DNA methylation compared to other genes
([33, 34], reviewed in [35]). This indicates that gene silencing
by chromatin conformational changes may precede DNA
methylation. Similar studies are now being performed at the
FXN locus to unravel the role of DNA methylation in FRDA
(Table 1).
Initial investigations of DNA methylation within the
FXN gene have revealed the hypermethylation of specific
CpG sites upstream of the GAA⋅TTC repeat sequence in
FRDA patient-derived lymphoblastoid cells compared to
cells derived from unaffected individuals [36]. However,
such Epstein-Barr virus-transfected lymphoblastoid cells are
known to frequently develop different DNAmethylation pat-
terns compared to those of primary peripheral blood leuko-
cytes [37]. Furthermore, FRDA is a systemic disorder that is
known to have differentially affected tissues and cell types.
To address these issues, Al-Mahdawi et al. (2008) studied
FRDA patient autopsy brain, heart, and cerebellum, the most
clinically relevant tissues in FRDA. This study revealed sig-
nificantly increased DNAmethylation at the upstream region
of the GAA⋅TTC repeats [38], consistent with previously
published data [36]. Similar DNA methylation changes were
also identified in brain, heart, and cerebellum tissues of two
lines of FRDA YAC transgenic mice (YG8 and YG22) [38].
However, the degree of DNA methylation in the transgenic
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Table 1: The summary of DNA methylation, histone methylation, and histone acetylation changes in multiple cell types and animal models
of FRDA.
Chromatin change Location Patients/cell type/animal model Reference(s)
DNA methylation ↑ GAA upstream Lymphoblasts, FRDA YAC transgenic mice, andprimary lymphocytes [36, 38–40]
H3K4me2/3 ↓
FXN promoter and exon 1 Lymphoblasts [61, 68, 69]
GAA upstream Lymphoblasts [68, 69]
GAA downstream Lymphoblasts [68, 69]
H3K9me2/3 ↑
FXN 5󸀠-UTR/promoter Primary fibroblasts and lymphoblasts [63, 68]
GAA upstream Lymphoblasts, FRDA YAC transgenic mice, and KIKImice [38, 60–62, 68, 69]
GAA downstream FRDA patients, FRDA YAC transgenic mice, andlymphoblasts [38, 60, 61, 68, 69]
H3K27me3 ↑
FXN 5󸀠-UTR/promoter Primary fibroblasts and lymphoblasts [63, 68]
GAA upstream Lymphoblasts [68]
GAA downstream Lymphoblasts [68]
H3K36me3 ↓ GAA upstream Lymphoblasts [61, 68, 69]
GAA downstream Lymphoblasts [61, 68, 69]
H3K79me2 ↓ GAA upstream Lymphoblasts [68]
GAA downstream Lymphoblasts [68]
H4K20me3 ↑ GAA upstream Lymphoblasts [68]
GAA downstream Lymphoblasts [68]
H4K5ac ↓
FXN promoter Lymphoblasts [69]
GAA upstream Lymphoblasts and KIKI mice [60, 62, 69]
GAA downstream FRDA patients, FRDA YAC transgenic mice, andlymphocytes [38, 62, 69]
H3K9ac ↓
FXN promoter FRDA patient brain tissue and lymphoblasts [38, 69]
GAA upstream FRDA patients, FRDA YAC transgenic mice,lymphoblasts cells, and KIKI mice [38, 60, 69]
GAA downstream FRDA patients, FRDA YAC transgenic mice, andlymphoblasts [38, 60, 69]
H4K8ac ↓ GAA upstream Lymphoblasts, FRDA patients, and KIKI mice [38, 60, 62, 69]
GAA downstream Lymphoblasts and FRDA patients [60, 69]
H4K12ac ↓
FXN promoter Lymphoblasts [60]
GAA upstream Lymphoblasts, FRDA patients, and FRDA YACtransgenic mice [38, 60]
GAA downstream Lymphoblasts, FRDA patients, and FRDA YACtransgenic mice [38, 60]
H3K14ac ↓
FXN promoter FRDA patients [38]
GAA upstream KIKI mice and lymphoblasts [62, 69]
GAA downstream FRDA YAC transgenic mice and lymphoblasts [69]
H4K16ac ↓
FXN promoter Lymphoblasts [62, 69]
GAA upstream Lymphoblasts, FRDA patients, FRDA YAC transgenicmice, and KIKI mice [38, 60, 62, 69]
GAA downstream Lymphoblasts, FRDA patients, FRDA YAC transgenicmice, and KIKI mice [38, 60, 62, 69]
↓: reduced, ↑: increased, H: histone, K: lysine, me2: dimethylation, me3: trimethylation, ac: acetylation, and HP: heterochromatin protein.
mice was not as severe as seen in FRDA patients, possibly
because the GAA⋅TTC repeats in the transgenic mice (<250
GAA⋅TTC repeats) are smaller than those in FRDA patients
(>700 GAA⋅TTC repeats).
The level of DNA methylation was also evaluated in
a large cohort of FRDA patients by the bisulfite-based
EpiTYPER MassARRAY technique [39]. This study showed
that the level of DNA methylation in FRDA patients
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is significantly elevated, especially the upstream of the
GAA⋅TTC repeats compared to normal individuals [39], in
line with the previously published data [36, 38]. It was also
reported that there is no difference in DNA methylation
between male and female cohorts of FRDA patients, indi-
cating no gender specificity of DNA methylation for FRDA.
Furthermore, another study has shown that the degree of
DNAmethylation in FRDApatients positively correlates with
the length of the GAA⋅TTC repeats and inversely correlates
with the age of the disease onset [40]. Thus, FRDA can
now be grouped together with other trinucleotide repeat
(TNR) expansion diseases in which an association with DNA
methylation has also been reported, including FRAXA [41],
myotonic dystrophy type I (DM1) [42], spinocerebellar ataxia
type 1 (SCA1) [43], and spinocerebellar ataxia type 7 (SCA7)
[44] (Figure 1).
2.2. Histone Modifications. The nucleosome, a basic subunit
of chromatin structure in eukaryotes, consists of an octamer
of two copies of each of the four histone proteins, H2A,
H2B, H3, and H4, along with a 147 bp of DNA [45]. Histone
proteins contain a globular C-terminal domain and an
unstructured N-terminal tail. The remarkable feature of the
histone tail is that it can contain many different modified
residues. Histone modifications can regulate gene expression
in several ways, by making the genetic loci more or less
accessible to the transcriptional machinery.
Although DNA methylation is considered to be a sta-
ble epigenetic modification, acetylation/deacetylation and
methylation/demethylation of histone proteins play more
flexible roles in the transcriptional regulation. Since histone
acetylation was first reported in 1964 [46], more than 60
different types of histonemodifications have been found [47].
Among these modifications, acetylation and methylation of
histones at lysine (and arginine) residues are highly dynamic
and are involved in several neurological disorders. The
histone acetylation at lysine residues is regulated by two
distinct families of enzymes with opposing action, histone
acetyltransferases (HATs) andhistone deacetylases (HDACs).
Similarly, histone lysine methylation is controlled by histone
methyltransferases (HMTs) and histone demethylases (e.g.,
LSD1 and JmjC), which have been linked to a number of
cellular processes including DNA repair, replication, and
transcriptional activation and repression [45]. Transcrip-
tional repression of genes occurs by the deacetylation and the
methylation of histone tails followed by the methylation of
CpG dinucleotides by one of three DNA methyltransferases
(DNMT1, DNMT3a, and DNMT3b), resulting in DNA with
high levels of CpG methylation [48].
Based on the homologies to yeast HDACs, 18 different
HDAC enzymes have been identified in mammals, and these
have been divided into four classes [49–53] (Table 2). Class I
consists of HDACs 1, 2, 3, and 8, which are similar to yeast
RPD3 deacetylase. Class II is further divided into class IIa,
which consists of HDACs 4, 5, 7, and 9, and class IIb, which
consists of HDACs 6 and 10. Class II HDACs have homology
to the yeast HDAC Had-1 gene. Class III HDACs include
sirtuins 1–7, also known as sirtuins, which have homology to
the yeast Sir2 gene. Lastly, class IV HDACs, which consist of
Table 2: The classification of HDACs in mammals.
Class HDACs Localisation
Class I
HDAC1 Nucleus
HDAC2 Nucleus
HDAC3 Nucleus
HDAC8 Nucleus
Class IIa
HDAC4 Nucleus/cytoplasm
HDAC5 Nucleus/cytoplasm
HDAC7 Nucleus/cytoplasm
HDAC9 Nucleus/cytoplasm
Class IIb HDAC6 Cytoplasm
HDAC10 Nucleus/cytoplasm
Class III SIRT1-7 Nucleus/cytoplasm
Class IV HDAC11 Nucleus/cytoplasm
only one HDAC, HDAC 11, do not have a significant homo-
logy with either class I or class II HDACs.
In recent years, advanced high-throughput techniques
have improved our ability to understand the role of the
epigenetic mechanisms in the pathogenesis of several neu-
rological disorders. Epigenetic changes, which may be due
to abnormally functioning HDACs, are already implicated
in several neurological disorders, such as DM1 [54], FRAXA
[55, 56], and spinal muscular atrophy (SMA) [57], which
result in the dysregulation of the acetylation state of the
chromatin. Initial findings suggested that FRDA is caused
by expanded GAA⋅TTC repeats, which trigger an abnormal
DNA structure [11, 58, 59]. However, recent studies have
indicated that FRDA may also be caused by increased levels
of DNA methylation, decreased histone acetylation, and
increased histone methylation [36, 38, 60–62].
Histone modifications at the FXN locus were first iden-
tified by the Gottesfeld lab, which reported lower levels of
several acetylated H3 and H4 lysine residues, together with
increased di- and trimethylation of H3K9 in the upstream
GAA⋅TTC regions of FRDA lymphoblastoid cells [60]. Since
then, other epigenetic modifications have been reported in
FRDA using multiple cell types and animal models (Table 1).
Greene et al. reported increased H3K9me2 levels within FXN
intron 1 in FRDA lymphoblastoid cells [36]. Al-Mahdawi et
al. reported histone modification changes at the promoter,
downstream, and upstream of the GAA⋅TTC repeats in
FRDA patient brain tissues and in an FRDA YAC transgenic
mouse model [38]. This study revealed that several histone
protein residues were hypoacetylated in the vicinity of the
FXN gene, especially H3K9, in both FRDA patients and
FRDA YAC transgenic mice. There is also a consistently
increased H3K9 di- and trimethylation of FRDA brain tissue
in all the three regions of the FXN gene. Furthermore, De
Biase et al. reported that FRDA patient fibroblasts have
significantly higher levels of H3K27me3 and H3K9me3 at
the FXN 5󸀠-UTR region, coupled with elevated levels of
heterochromatin protein 1 (HP1), compared to those of
normal fibroblasts [63]. In mammals, it is generally accepted
that heterochromatin is associated with the hypoacetylation
of certain histone proteins, mainly H3K9, and increased
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Figure 1: The position of DNA methylation and CTCF binding sites within TNR expansion loci. (a) FRAXA, (b) DM1, (c) SCA7, and (d)
FRDA. Grey boxes represent regions of disease-associated DNA methylation. Arrow marks represent the direction of transcription. Red
triangles indicate the position of repeats. This image was adapted from [139].
histone methylation levels, primarily H3K9me3, H3K27me3,
and H4K20me3 [64–67]. In FRDA cells, increases in all
of these histone modifications have been identified within
the FXN gene, predominantly at the region immediately
upstream of the expanded GAA⋅TTC repeats, indicating
that the FXN gene is under a form of heterochromatin
silencing machinery (Figure 2) [38, 60, 61, 63, 68, 69]. On
the other hand, histone modifications such as H3K4me3,
H3K36me3, and H3K79me3 are associated with a more open
chromatin state and active gene expression. H3K4me3 is
particularly associated with the initiation of gene transcrip-
tion, while H3K36me3 and H3K79me3 are associated with
the elongation of gene transcription. Recent studies have
reported decreased levels of H3K36me3 and H3K79me3 at
the upstream and the downstream GAA repeat regions of
the FXN gene in FRDA cells, indicating that there is a defect
in the transcription elongation [61, 68, 69]. Decreased levels
of H3K4me3 have also been identified at the upstream GAA
repeat region, but not at the promoter region, which suggests
a more pronounced defect of the postinitiation and elonga-
tion stages of FXN gene expression rather than an early tran-
scription initiation defect (Figure 2) [61, 68, 69]. In summary,
there is a good evidence that the reduction of frataxin protein
expression in FRDA is primarily caused by GAA repeat
expansion-induced transcriptional blockage. However, the
exact mechanism remains elusive and the potential defects in
frataxin translation have not yet been discounted [70, 71].
2.3. The Role of Antisense Transcription and CTCF. Recent
completion of the ENCODE project has shown that the
human genome is comprised of approximately 21,000 protein
coding genes, occupying only 3% of the genome [72, 73].
However, a total of 76% of the genome is transcribed, and
most of this transcriptional output is made up of noncoding
RNAs (ncRNAs) [72, 74–76]. Mammalian ncRNAs have
been increasingly recognised as important regulators that
are associated with various processes including RNA inter-
ference, imprinting, alternative splicing, and transcriptional
inhibition [77–81].
Antisense transcription is a phenomenon where the
opposite strand (antisense strand) to the protein coding
strand (sense strand) is transcribed. Antisense RNA has been
ascribed to roles in several molecular mechanisms, includ-
ing the regulation of gene expression. Recent studies have
shown that antisense transcripts can be detected in various
genes, including the nonpathogenic alleles, known as natural
antisense transcripts (NATs). Antisense transcripts can also
be associated with microsatellite repeat expansion diseases
such as HD [82], FRAXA [83, 84], SCA7 [85], SCA8 [86], and
DM1 [54, 87]. In general, the level of antisense transcription
is significantly lower than that of the coding sense transcripts.
Nevertheless, multiple reports have recently shown that
antisense transcripts can be involved in either the inhibition
of the same gene from where they originate (cis-acting) or
the inhibition of genes at different locations (trans-acting)
[88–90]. Therefore, the study of antisense transcription in
gene silencing machinery may provide further insight into
the mechanisms of neurodegenerative disorders, including
FRDA. To identify the presence of any antisense transcript
in FRDA, De Biase and colleagues [63] performed a strand-
specific reverse transcription PCR using a primer located
upstream of FXN transcription start site 3 (TSS3). This study
revealed the significantly increased levels of frataxin antisense
transcript 1 (FAST1) at the vicinity of the transcription start
site (TSS) of the FXN gene [63]. Furthermore, elevated
levels of HP1 were identified at this locus in FRDA patient-
derived fibroblasts compared to the fibroblasts of unaffected
individuals [63]. It has been suggested that these aberrant
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Figure 2: The FXN chromatin organization in normal individuals and FRDA patients. (a) In normal individuals, the promoter contains
H3K4me3 andH3K36me3, while downstream regions contain H3K79me2 andH3K36me3, marks for transcription initiation and elongation,
respectively. All regions contain H3K9ac, a mark for active open chromatin. There is CTCF binding at the 5󸀠-UTR. (b) In FRDA, depletion
of CTCF may trigger the FAST-1 antisense transcription that may lead to the deacetylation of histones and the increase of H3K9me3 at the
promoter and other regions of the gene. However, the levels of H3K4me3 and H3K36me3 are not substantially changed at the promoter
(indicated by brackets), suggesting that there may be little deficiency of transcription initiation. The repressive histone marks, H3K27me3,
H4K20me3 and H3K9me3, are observed throughout the gene, but most prominently at the upstream GAA repeat region, along with an
increased DNA methylation. There are also reduced levels of H3K36me3 and H3K79me2 at the upstream GAA region, indicative of a defect
of transcription elongation in FRDA.
features in FRDA may be associated with the depletion of
CCCTC-binding factor (CTCF) that eventually leads to the
disease-associated epigenetic changes for the transcriptional
repression of the FXN gene. However, it is still unclear how
CTCF is depleted in FRDA and how this leads to FXN gene
silencing.
CTCF is a highly conserved 11-zinc finger (ZF) nuclear
protein, originally recognised as a transcription factor that
binds to avian andmammalianMYC promoters [91]. CTCF is
involved in a variety of transcriptional regulatory functions,
including transcriptional activation, transcriptional repres-
sion, and genomic imprinting [92]. Additionally, CTCF is
reported to have a role in inducing RNA polymerase II medi-
ated alternative splicing [93]. DNA methylation typically
prevents the binding of CTCF. However, recent studies have
revealed that CTCF can also prevent the spreading of DNA
methylation and thusmaintainsDNAmethylation-free zones
in the genome [94, 95]. Furthermore, CTCF binding sites
have been identified in the repeat expansion flanking regions
of several TNR disorders, such as FRAXA [84], DM1 [96],
and SCA7 [44] (Figure 1). For FRDA, CTCF binding sites
have been identified in the 5󸀠-UTR region of the FXN gene
in fibroblasts [63] and in cerebellum tissues (R. Mouro Pinto,
S. Al-Mahdawi, andM. Pook unpublished observations) (Fig-
ure 1).The loss of CTCFbinding at theDM1CTGexpansion is
associated with the spread of heterochromatin and local CpG
methylation [54]. Similarly, the GAA⋅TTC repeat expansion
in FRDA is also associated with the depletion of CTCF
binding in the 5󸀠-UTR region of the FXN gene, which may
trigger the enrichment of heterochromatin formation and
DNAmethylation in the upstreamGAA region, although the
5󸀠-UTR region of the FXN gene does not show any apparent
increase in DNA methylation [36, 38, 63]. These findings
support the hypothesis that CTCF prevents the spread of
heterochromatin at the TNR loci, although further analysis is
still required to evaluate the series of events occurring in the
context of chromatin conformational changes, CTCF binding
modulation, and DNA methylation for each specific TNR
expansion disease.
3. Epigenetic Therapy for FRDA
Thefinding thatmany humandiseases, including cancer, have
an epigenetic aetiology has encouraged the development of a
new treatment option that can be termed “epigenetic therapy.”
Advances in epigenetic research have identified several drug
compounds that specifically target enzymes involved in the
alteration of the epigenetic states of genes, thus leading to the
activation of the previously silenced genes ([60, 61], reviewed
in [97]). Such drug compounds have discovered that the
alteration of DNAmethylation patterns and the modification
of histones and several of these agents are currently being
tested in clinical trials. Epigenetic therapies have already
been used widely for cancer treatment, and their use is
now extending to other diseases. FRDA is a disorder that
currently has no effective therapy. However, since FRDA
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is associated with several epigenetic changes that result in
a partial deficiency of frataxin mRNA and protein, it is
suggested that reversing the epigenetic changes to upregulate
frataxin expression may prove to be an effective therapy.
Indeed, such epigenetic therapy would have two distinct
advantages in FRDA: (a) a negative immune response to
increased frataxin protein would be unlikely, since the body
is already exposed to residual frataxin levels and (b) only a
slight increase in frataxin levels may be needed to have a
significant clinical effect, since heterozygous FRDA carriers
are phenotypically normal.
3.1. DNA Demethylating Agents. Since FRDA and other neu-
rodegenerative disorders are associated with the increased
levels of DNA methylation, one can propose the use of
DNA demethylating agents to reduce DNA methylation
and thereby activate the previously silenced genes. DNA
demethylating agents inhibit the methylation of DNA by
the nonspecific inhibition of DNMTs. DNA demethylating
agents are generally divided into two categories, nucleoside
analogue DNMT inhibitors and nonnucleoside analogue
DNMT inhibitors. Nucleoside analogue DNMT inhibitors,
which include 5-azacytidine (5-aza-CR or Vidaza), 5-aza-2󸀠-
deoxycytidine (5-aza-CdR or Decitabine), and Zebularine,
are analogues of cytosine, the nucleoside base that is methy-
lated by DNMTs. 5-aza-CdR, which is an FDA-approved
drug, has been tested in several phases I, II, and III clinical
trials finding the most promising benefits in leukaemia
patients [98], especially those affected by myelodysplastic
syndrome (MDS) [99–101]. The treatment of lymphoblastoid
cells from FRAXA patients with 5-aza-CdR, either alone
[102] or in combination with HDAC inhibitors [103] effici-
ently reverses the FMR1promoter hypermethylation and rest-
ores mRNA and protein levels to normal. This has led to
the consideration of DNA demethylating agents as a poten-
tial therapy for neurodegenerative disorders. Thus far, there
have been no reports of describing the use of DNA demethy-
lating agents as a therapeutic approach for FRDA. How-
ever, our lab has recently studied the effect of several
DNA demethylating agents on FRDA human and transgenic
mouse primary fibroblasts (C. Sandi, unpublished observa-
tions). Our preliminary findings show 1- to 2-fold increases
of FXN expression in FRDA transgenic mouse cells but
decreased FXN expression in human FRDA cells, following
the treatment with DNA demethylating agents (5-aza-CdR
and Zebularine). Therefore, our preliminary results suggest
that DNA demethylating agents are not likely to be a useful
therapy for FRDA. The discrepancy between our findings
in mouse and human cells is possibly due to a difference
in the regulatory mechanisms of gene expression between
the two species, indicating a need for further investiga-
tion. Finally, sequence-specific DNA demethylating agents,
such as the oligonucleotide antisense inhibitor MG98 [104–
107], may be useful for future therapeutic approaches in
reducing the specific DNA methylation. In addition, the
uses of naturally available green tea and derivatives have
also shown beneficial effects in reducing the DNA methy-
lation in various cancers [108–111]. Therefore, consideration
of these compounds, especially those that are already in
clinical trials, may be promising for future FRDA ther-
apy.
3.2. Histone Deacetylase (HDAC) Inhibitors. Over the past
decade, substantial progress has been made in the develop-
ment of drugs that target the epigenetic changes in chromatin.
Several HDAC inhibitors have been developed, ranging from
the complicated chemical structures of bacterial or fungal
origin, such as trichostatin A (TSA), to simple compounds
such as butyrate. HDAC inhibitors can affect transcription by
inducing the acetylation of histones, transcriptional factors,
and other proteins that regulate transcription. They act pri-
marily by increasing the global histone acetylation, followed
by transcriptional activation of the epigenetically silenced
genes through the relaxation of chromatin conformation,
although some HDAC inhibitors may also promote the
acetylation of nonhistone proteins [112].
In view of the recent identification of alterations in
histone acetylation in FRDA, it has been postulated that the
reversal or the inhibition of these histonemodifications could
represent a potential therapeutic route for FRDA [60, 113].
An initial study to screen for frataxin-increasing compounds
first demonstrated a small effect of the general HDAC
inhibitor sodium butyrate on FXN gene activity using an
EGFP reporter cell line [114]. Subsequently, the treatment of
FRDA lymphoblastoid cells using a selection of commercially
available HDAC inhibitors revealed that only the benzamide
compound BML-210 produced a significant increase of FXN
mRNA expression [60], although other HDAC inhibitors
showed a more pronounced increase of histone acetylation
without any increase in FXN expression, indicating a degree
of compound specificity for FXN gene silencing. Further
studies using multiple cell types and mice identified three
pimelic o-aminobenzamide compounds, 106, 136, and 109,
each of which has undergone investigations to determine
safety, efficacy, and pharmacokinetic profile in short-term
treatments of FRDA patient-derived cells and mice [62, 115–
118] and a long-term treatment in FRDAYAC transgenicmice
[71]. Compound 109, which emerged as the most promising
compound for FRDA treatment, is currently undergoing
early clinical trials. However, other HDAC inhibitors such as
nicotinamide [119], sirtinol [120], splitomicin [121], LBH589
[122], and oxamflatin [123] have shown positive effects in
other diseases including cancer and/or neurodegenerative
disorders, and these compounds may also be considered for
future FRDA therapy.
Since DNA methylation and histone modifications are
both known to act epigenetically, it would perhaps be benefi-
cial to use DNA demethylating agents and HDAC inhibitors
together to investigate the potential for a more pronounced
synergistic effect on increasing frataxin expression. A syn-
ergistic effect of DNA demethylating agents and HDAC
inhibitors has previously been shown in the treatment of
several cancers [124, 125] and neurodegenerative disorders
[103]. Small noncoding RNAs, such as microRNAs, have
also been implicated in several neurodegenerative disorders
including AD [126], HD [127], and FRDA [128]. The elevated
levels of miR-886-3p in FRDA are believed to be associated
with the downregulation of the FXN gene, and the use of
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anti-miR-886-3p or the HDAC inhibitor 4b alone has been
shown to partially reverse FXN gene repression by reducing
miR-886-3p levels [128]. Therefore, it would be interesting
to investigate the combined effect of anti-microRNA and
HDAC inhibitor compounds on the activation of FXN gene
transcription.
3.3. Antigene RNA- (agRNA-) Based Therapies. RNA inter-
ference (RNAi) is a posttranscriptional phenomenon, where
sequence-specific gene silencing is achieved by chromatin
remodellingwhich can be triggered by a small pool of double-
stranded RNAs with approximately 21 to 28 nucleotides in
length [129]. Antigene RNAs (agRNAs) are small duplex
RNAs with 19 bp length (2-nt overhang at 3󸀠 end) that target
gene promoters, and depending on the target sequence and
the cell type, agRNAs can either silence [130–132] or activate
the gene transcription [133–135]. Since agRNAs target in a
sequence specific manner, it may be possible to modulate
agRNAs to activate the gene expression in disease-associated
genes where gene activation is essential, as with FRDA.
Importantly, agRNAs can target either sense or antisense
strands and coding or noncoding RNA transcripts [134].
Therefore, considering the use of agRNA to activate the FXN
gene by targeting the FXN promoter or the FAST1 transcript
may be useful, since both mechanisms may be involved in
reversing FXN gene silencing and thus FRDA pathology.
4. Conclusion and Future Studies
Due to the identification of several epigenetic changes, FRDA
can now be considered as an epigenetic disease. It remains
to be seen whether further epigenetic marks, such as the
recently identified 5-hydroxymethyl cytosine residue, may
also eventually prove to have an effect on the regulation
of FXN gene expression [136, 137]. The epigenetic marks
already implicated in FRDA disease pathology have enabled
the development of drugs that can target these changes and
partially reverse the disease pathology. However, epigenetic
therapies are generally nonspecific, with off-target effects,
and the lack of specific drugs that target the FXN gene
locus to reverse the epigenetic changes may require further
consideration. Since FRDA is a multisystem disorder, it may
be useful to simultaneously administer two or more drugs to
examine the synergistic treatment effects. To identify novel
epigenetic-based FRDA therapeutic compounds for future
testing, various drug screening systems have been developed
and are being utilised in several labs, including our own
lab (see review [138]). Furthermore, to develop an effective
system for testing potential FRDA therapies, cell and animal
models are considered essential, and several model systems
are currently under investigation (see review [138]).
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